secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zomedica Corp. (ZOMDF)
CIK:        0001684144
Form:       8-K
Filed at:   2022-03-01T23:59:59+00:00
Accession:  0001654954-22-002346
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zomedica reports 2021 full-year revenue of $4.1M; net loss $18.4M
-----------------------------------------------------------------

- Total revenue of $4.1M in 2021, vs $0 in 2020; gross margin 73.9%.
- Net loss $18.4M ($0.05 diluted EPS) vs $16.9M ($0.19) in 2020.
- PulseVet Q4 revenue $4.0M, up 66% YoY as standalone; TRUFORMA Q4 revenue $73k, up 224% QoQ.
- Cash and equivalents $195M at Dec 31, 2021 vs $62M a year earlier.
- Expected to launch eACTH assay in Q2 2022; evaluating M&A opportunities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1684144/000165495422002346/0001654954-22-002346-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1684144/000165495422002346/zom_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-22-002346

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer